Market Closed -
Nasdaq
03:59:46 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
25.22
USD
|
+0.10%
|
|
-11.24%
|
-40.13%
|
Fiscal Period: Marzo |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
850.7
|
1,571
|
641.3
|
2,005
|
4,694
|
3,685
|
-
|
-
|
Enterprise Value (EV)
1 |
850.7
|
1,171
|
147.5
|
1,628
|
4,059
|
3,155
|
3,364
|
3,589
|
P/E ratio
|
-10.1
x
|
-13.1
x
|
-3.85
x
|
-9.07
x
|
-17.2
x
|
-11.3
x
|
-12
x
|
-17.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
49
x
|
12.8
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
44.8
x
|
12.5
x
|
EV / EBITDA
|
-
|
-10.8
x
|
-0.95
x
|
-7.47
x
|
-14.4
x
|
-9.54
x
|
-14.1
x
|
-7.97
x
|
EV / FCF
|
-15.9
x
|
-14
x
|
-1.39
x
|
-8.64
x
|
-18.9
x
|
-10.9
x
|
-10.3
x
|
-14.8
x
|
FCF Yield
|
-6.28%
|
-7.13%
|
-72.1%
|
-11.6%
|
-5.29%
|
-9.19%
|
-9.71%
|
-6.78%
|
Price to Book
|
-
|
3.6
x
|
1.29
x
|
5.58
x
|
7.62
x
|
8.99
x
|
23.5
x
|
-
|
Nbr of stocks (in thousands)
|
54,655
|
97,971
|
116,396
|
129,260
|
145,293
|
146,054
|
-
|
-
|
Reference price
2 |
15.56
|
16.04
|
5.510
|
15.51
|
32.31
|
25.23
|
25.23
|
25.23
|
Announcement Date
|
6/29/20
|
6/1/21
|
6/8/22
|
5/22/23
|
5/29/24
|
-
|
-
|
-
|
Fiscal Period: Marzo |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
75.14
|
288
|
EBITDA
1 |
-
|
-108.1
|
-155.9
|
-218.1
|
-282.5
|
-330.5
|
-238.7
|
-450.1
|
EBIT
1 |
-66.08
|
-108.1
|
-156
|
-218.3
|
-282.7
|
-340.2
|
-339
|
-241.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-451.09%
|
-83.75%
|
Earnings before Tax (EBT)
1 |
-66.29
|
-107.8
|
-156.8
|
-211
|
-258.8
|
-332.2
|
-392.4
|
-197.1
|
Net income
1 |
-66.39
|
-107.4
|
-156.7
|
-211
|
-259.3
|
-328.7
|
-339.8
|
-226.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-452.25%
|
-78.75%
|
EPS
2 |
-1.540
|
-1.220
|
-1.430
|
-1.710
|
-1.880
|
-2.234
|
-2.104
|
-1.450
|
Free Cash Flow
1 |
-53.39
|
-83.54
|
-106.4
|
-188.4
|
-214.6
|
-290
|
-326.8
|
-243.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-434.87%
|
-84.43%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/29/20
|
6/1/21
|
6/8/22
|
5/22/23
|
5/29/24
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
2026 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-47.19
|
-40.33
|
-49.57
|
-63.98
|
-64.2
|
-78.42
|
-61.74
|
-61.44
|
-80.82
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-41.27
|
-47.23
|
-40.38
|
-49.61
|
-64.03
|
-64.26
|
-78.48
|
-61.8
|
-61.55
|
-80.88
|
-81.58
|
-84.88
|
-86.71
|
-93.84
|
-97.12
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-41.38
|
-47.18
|
-40.02
|
-47.67
|
-62.84
|
-60.42
|
-73.95
|
-58.21
|
-51.53
|
-75.09
|
-77.34
|
-81.11
|
-83.16
|
-90.63
|
-97.12
|
Net income
1 |
-41.38
|
-47.17
|
-40.37
|
-47.93
|
-63.23
|
-59.43
|
-73.94
|
-58.66
|
-51.42
|
-75.32
|
-77.19
|
-80.94
|
-83.21
|
-90.31
|
-97.12
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3600
|
-0.4100
|
-0.3500
|
-0.4100
|
-0.4900
|
-0.4600
|
-0.5700
|
-0.4500
|
-0.3600
|
-0.5200
|
-0.5325
|
-0.5512
|
-0.5562
|
-0.5988
|
-0.6350
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/4/22
|
6/8/22
|
8/5/22
|
11/4/22
|
2/3/23
|
5/22/23
|
8/10/23
|
11/9/23
|
2/12/24
|
5/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
400
|
494
|
377
|
635
|
530
|
321
|
95.8
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-53.4
|
-83.5
|
-106
|
-188
|
-215
|
-290
|
-327
|
-243
|
ROE (net income / shareholders' equity)
|
-
|
-44.3%
|
-36.4%
|
-50.7%
|
-52.9%
|
-62.3%
|
-66%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-48.4%
|
-44.6%
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
536.2
|
737
|
-
|
-
|
Book Value Per Share
2 |
-
|
4.460
|
4.280
|
2.780
|
4.240
|
2.810
|
1.070
|
-
|
Cash Flow per Share
2 |
-
|
-0.9500
|
-0.9700
|
-1.530
|
-1.550
|
-1.350
|
0.6200
|
-
|
Capex
1 |
0.03
|
0.21
|
0.25
|
0.2
|
0.36
|
0.6
|
7.7
|
0.4
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
10.25%
|
0.14%
|
Announcement Date
|
6/29/20
|
6/1/21
|
6/8/22
|
5/22/23
|
5/29/24
|
-
|
-
|
-
|
Last Close Price
25.23
USD Average target price
50.14
USD Spread / Average Target +98.74% Consensus |
1st Jan change
|
Capi.
|
---|
| -40.13% | 3.68B | | +46.19% | 55.7B | | -6.14% | 39.57B | | +39.67% | 39.91B | | -6.65% | 28.16B | | +12.33% | 26.3B | | -21.78% | 18.94B | | -0.35% | 12.12B | | +24.18% | 12.12B | | +28.38% | 12.17B |
Other Biotechnology & Medical Research
|